Key points are not available for this paper at this time.
Collectively, these data provide strong preclinical evidence that combinatorially targeting immunosuppression in malignant glioma is a strategy that has high potential value for future clinical trials in patients with GBM.
Wainwright et al. (Wed,) studied this question.